The UK and US have reached a significant bilateral deal that will guarantee no tariffs on UK medicine products being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to raise expenditure on pharmaceuticals through the public health system. This commitment ensures that tariffs on these vital exports will remain at nothing for a timeframe of 36 months.
This deal follows earlier warnings to significantly raise duties on patented pharmaceutical imports, with increases floated reaching double the cost.
"This deal between the Britain bolsters the international landscape for new treatments and establishes long-overdue equity to American-British medicine commerce," a release said.
Economic Impact
Pharmaceuticals are one of the the United Kingdom's most significant exports to the United States, which is clearly the largest market for leading UK drugmakers.
Trade data reveal that in the 12 months to the end of last September, the UK shipped medicines worth over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that span.
"This deal secures work, increases investment and facilitates the UK to become a global hub for biotech and pharma," a minister commented.
Key British Pledges
The agreement entails several key changes from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be restricted at 15%. Previously, refunds exceeded 20%.
Broader Context
The pact comes amid a long-running row between the sector and the ministers over spending levels and NHS adoption.
This friction were exacerbated by claims that American consumers were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several major manufacturing plans in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been directed toward American operations.
The Science Minister stated that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the past decade.
